Similarly, dasatinib combined with anti-PD-1 therapy has shown enhanced efficacy in acute lymphocytic leukemia (ALL) [76], colon cancer [77,78], and non-small cell lung cancer (NSCLC) [79]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.